Trial Profile
Optimizing Susceptibility to CCR5 Antagonist Response
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Mar 2015
Price :
$35
*
At a glance
- Drugs Maraviroc (Primary) ; Antiretrovirals
- Indications HIV-1 infections
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms OSCAR
- 23 Jun 2011 New trial record